Elodie Pliquet

Title: Elodie Pliquet: Innovator in Telomerase Research

Introduction

Elodie Pliquet is a prominent inventor based in Gentilly, France. She has made significant contributions to the field of biotechnology, particularly in the development of innovative vaccines targeting telomerase-related conditions. With a total of 3 patents to her name, her work is paving the way for new therapeutic approaches.

Latest Patents

One of her latest patents is the "Telomerase encoding DNA vaccine." This invention provides a nucleic acid construct that encodes a human telomerase reverse transcriptase (hTERT) protein, which is devoid of telomerase catalytic activity and a nucleolar localization signal. The construct is designed to trigger an immune response against cells that overexpress telomerase, particularly dysplastic or tumor cells. Another notable patent is the "Recombinant measles vaccine expressing hTERT." This invention involves a recombinant measles virus plasmid capable of expressing an hTERT protein fused at the N-terminus with a protein that enhances the addressing of the hTERT protein to the proteasome. This vaccine aims to prevent or treat tumors in patients.

Career Highlights

Elodie has worked with several companies, including Invectys and Invectys SAS. Her work in these organizations has been instrumental in advancing research in immunotherapy and vaccine development.

Collaborations

Elodie has collaborated with notable professionals in her field, including Pierre Langlade Demoyen and Simon Wain-Hobson. These collaborations have enriched her research and contributed to her innovative projects.

Conclusion

Elodie Pliquet is a trailblazer in the field of biotechnology, with her patents reflecting her commitment to advancing medical science. Her innovative approaches to vaccine development are set to make a significant impact on the treatment of cancer and other diseases.